Literature DB >> 25556204

Increased number of white matter lesions in patients with familial cerebral cavernous malformations.

M J Golden1, L A Morrison2, H Kim3, B L Hart4.   

Abstract

BACKGROUND AND
PURPOSE: Familial cerebral cavernous malformations, an autosomal dominant disorder, result in excess morbidity and mortality in affected patients. The disorder is most prevalent in the Southwest United States, where the affected families are most often carriers of the CCM1-KRIT1 Common Hispanic Mutation. The brain and spinal cord parenchyma in these individuals is usually affected by multiple cavernous malformations. Previous studies have shown abnormalities of endothelial cell junctions and the blood-brain barrier in cerebral cavernous malformations. Endothelial cell abnormalities have also been described in pathologic studies of white matter hyperintensities. We compared the prevalence of white matter hyperintensities in a population with known familial cerebral cavernous malformations.
MATERIALS AND METHODS: We examined 191 subjects with familial cerebral cavernous malformations who were enrolled into an institutional review board-approved study. All carry the same Common Hispanic Mutation in the CCM1 gene. Each subject underwent 3T MR imaging, including gradient recalled-echo, SWI, and FLAIR sequences. The number of cavernous malformations and the number of nonhemorrhagic white matter hyperintensities were counted. Subjects older than 60 years of age were excluded due to the high prevalence of white matter lesions in this population, and children younger than 6 were excluded due to potential sedation requirements. Logistic regression analysis was performed to determine the prevalence of abnormal white matter hyperintensities in those with familial cerebral cavernous malformations compared with healthy controls or those with sporadic cerebral cavernous malformation within the familial cerebral cavernous malformations group; it was also performed to evaluate the associations between abnormal white matter hyperintensities and age, sex, headaches, thyroid disease, diabetes, hypertension, hyperlipidemia, seizure history, or modified Rankin Scale score.
RESULTS: Familial CCM1 carriers have a higher prevalence of abnormal white matter hyperintensities (15.4%) compared with both control populations (2.1% and 2.5%, respectively) (P < .05). Logistic regression showed no statistical association with sex, headaches, hyperlipidemia, hypertension, thyroid disease, seizure history, number of cerebral cavernous malformations, or modified Rankin Scale score among those with familial cerebral cavernous malformation. An expected correlation with age was shown.
CONCLUSIONS: Familial CCM1 carriers have not only an increased number of cerebral cavernous malformations but also an increased number of white matter T2 hyperintensities, spatially distinct from cerebral cavernous malformations, which exceeded that of a healthy population. Clinical findings did not explain the association with abnormal white matter hyperintensities in the familial cerebral cavernous malformation population. To our knowledge, these relationships have not been previously reported. This finding suggests an additional manifestation of endothelial abnormalities in this population.
© 2015 by American Journal of Neuroradiology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25556204      PMCID: PMC4433814          DOI: 10.3174/ajnr.A4200

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  20 in total

1.  Prevalence of white matter hyperintensities in a young healthy population.

Authors:  Ramona O Hopkins; Callie J Beck; David L Burnett; Lindell K Weaver; Jeff Victoroff; Erin D Bigler
Journal:  J Neuroimaging       Date:  2006-07       Impact factor: 2.486

2.  Incidental findings on brain MRI in the general population.

Authors:  Meike W Vernooij; M Arfan Ikram; Hervé L Tanghe; Arnaud J P E Vincent; Albert Hofman; Gabriel P Krestin; Wiro J Niessen; Monique M B Breteler; Aad van der Lugt
Journal:  N Engl J Med       Date:  2007-11-01       Impact factor: 91.245

3.  Ultrastructural characteristics of hemorrhagic, nonhemorrhagic, and recurrent cavernous malformations.

Authors:  Jian Tu; Marcus A Stoodley; Michael K Morgan; Kingsley P Storer
Journal:  J Neurosurg       Date:  2005-11       Impact factor: 5.115

4.  Impairment of tight junctions and glucose transport in endothelial cells of human cerebral cavernous malformations.

Authors:  Hannah Schneider; Mariella Errede; Nils H Ulrich; Daniela Virgintino; Karl Frei; Helmut Bertalanffy
Journal:  J Neuropathol Exp Neurol       Date:  2011-06       Impact factor: 3.685

5.  Ultra-fast low-angle rapid acquisition and relaxation enhancement (UFLARE) in patients with epilepsy.

Authors:  S H Eriksson; A Stepney; M R Symms; F G Woermann; T Niendorf; G J Barker; B Kendall; J M Stevens
Journal:  Neuroradiology       Date:  2001-12       Impact factor: 2.804

6.  Clinical application of neuroimaging in epilepsy.

Authors:  U C Wieshmann
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-04       Impact factor: 10.154

7.  Cerebral cavernous malformations proteins inhibit Rho kinase to stabilize vascular integrity.

Authors:  Rebecca A Stockton; Robert Shenkar; Issam A Awad; Mark H Ginsberg
Journal:  J Exp Med       Date:  2010-03-22       Impact factor: 14.307

8.  White matter lesions in patients with localization-related epilepsy.

Authors:  Jacobus F A Jansen; Marielle C G Vlooswijk; Hj Marian Majoie; Marc C T F M de Krom; Albert P Aldenkamp; Paul A M Hofman; Walter H Backes
Journal:  Invest Radiol       Date:  2008-08       Impact factor: 6.016

9.  The natural history of familial cavernous malformations: results of an ongoing study.

Authors:  J M Zabramski; T M Wascher; R F Spetzler; B Johnson; J Golfinos; B P Drayer; B Brown; D Rigamonti; G Brown
Journal:  J Neurosurg       Date:  1994-03       Impact factor: 5.115

10.  KRIT-1/CCM1 is a Rap1 effector that regulates endothelial cell cell junctions.

Authors:  Angela Glading; Jaewon Han; Rebecca A Stockton; Mark H Ginsberg
Journal:  J Cell Biol       Date:  2007-10-22       Impact factor: 10.539

View more
  7 in total

Review 1.  Genetics of cerebral cavernous malformations: current status and future prospects.

Authors:  H Choquet; L Pawlikowska; M T Lawton; H Kim
Journal:  J Neurosurg Sci       Date:  2015-04-22       Impact factor: 2.279

2.  Vascular permeability in cerebral cavernous malformations.

Authors:  Abdul G Mikati; Omaditya Khanna; Lingjiao Zhang; Romuald Girard; Robert Shenkar; Xiaodong Guo; Akash Shah; Henrik B W Larsson; Huan Tan; Luying Li; Matthew S Wishnoff; Changbin Shi; Gregory A Christoforidis; Issam A Awad
Journal:  J Cereb Blood Flow Metab       Date:  2015-05-13       Impact factor: 6.200

3.  Common transcriptome, plasma molecules, and imaging signatures in the aging brain and a Mendelian neurovascular disease, cerebral cavernous malformation.

Authors:  Janne Koskimäki; Sean P Polster; Yan Li; Sharbel Romanos; Abhinav Srinath; Dongdong Zhang; Julián Carrión-Penagos; Rhonda Lightle; Thomas Moore; Seán B Lyne; Agnieszka Stadnik; Kristina Piedad; Ying Cao; Robert Shenkar; Alexey V Dimov; Nick Hobson; Gregory A Christoforidis; Timothy Carroll; Romuald Girard; Issam A Awad
Journal:  Geroscience       Date:  2020-06-17       Impact factor: 7.713

4.  NIR-II window tracking of hyperglycemia induced intracerebral hemorrhage in cerebral cavernous malformation deficient mice.

Authors:  Abdul K Parchur; Zhi Fang; Jaidip M Jagtap; Gayatri Sharma; Christopher Hansen; Shayan Shafiee; Wenquan Hu; Qing R Miao; Amit Joshi
Journal:  Biomater Sci       Date:  2020-08-21       Impact factor: 7.590

5.  Cerebral cavernous malformations are driven by ADAMTS5 proteolysis of versican.

Authors:  Courtney C Hong; Alan T Tang; Matthew R Detter; Jaesung P Choi; Rui Wang; Xi Yang; Andrea A Guerrero; Carl F Wittig; Nicholas Hobson; Romuald Girard; Rhonda Lightle; Thomas Moore; Robert Shenkar; Sean P Polster; Lauren M Goddard; Aileen A Ren; N Adrian Leu; Stephanie Sterling; Jisheng Yang; Li Li; Mei Chen; Patricia Mericko-Ishizuka; Lukas E Dow; Hideto Watanabe; Markus Schwaninger; Wang Min; Douglas A Marchuk; Xiangjian Zheng; Issam A Awad; Mark L Kahn
Journal:  J Exp Med       Date:  2020-10-05       Impact factor: 14.307

6.  Thrombospondin1 (TSP1) replacement prevents cerebral cavernous malformations.

Authors:  Miguel Alejandro Lopez-Ramirez; Gregory Fonseca; Hussein A Zeineddine; Romuald Girard; Thomas Moore; Angela Pham; Ying Cao; Robert Shenkar; Bart-Jan de Kreuk; Frederic Lagarrigue; Jack Lawler; Christopher K Glass; Issam A Awad; Mark H Ginsberg
Journal:  J Exp Med       Date:  2017-09-28       Impact factor: 14.307

7.  Cytochrome P450 and matrix metalloproteinase genetic modifiers of disease severity in Cerebral Cavernous Malformation type 1.

Authors:  Hélène Choquet; Eliana Trapani; Luca Goitre; Lorenza Trabalzini; Amy Akers; Marco Fontanella; Blaine L Hart; Leslie A Morrison; Ludmila Pawlikowska; Helen Kim; Saverio Francesco Retta
Journal:  Free Radic Biol Med       Date:  2016-01-19       Impact factor: 7.376

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.